Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 28 July 2006
Extended collaboration on novel cancer
targets
Oxford BioMedica and Arius Research announced the first milestone and decision to move into next phase of collaboration to discover and characterise novel cancer targets and downstream therapeutics
Under the agreement, antigen targets and antibodies can be out-licensed to commercial partners or developed by one or both of the companies In the initial phase of the collaboration, which began on 25 July 2002, 50 functional anti-cancer antibodies from the Arius library were used by Oxford BioMedica to mine for novel targets
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
The decision to extend the collaboration comes from the successful identification of three targets that offer opportunities in a range of cancer diseases.
The new collaboration will focus on one that is over-expressed in gastrointestinal and other cancers and is related to cancer metastasis.
The success of the initial phase is due to synergies between the two companies.
Arius's Functionfirst discovery platform starts with human tumour cells and selects for antibodies with direct anti-cancer effects.
By not starting from a known target, the Arius platform offers opportunities to discover novel targets or the unique spots on a target that are important in triggering cancer cell death.
Oxford BioMedica has a number of proprietary technologies from its gene discovery and immunotherapy programmes and has both the technical skills to develop products and the business development experience to market them.
Arius's president and CSO, David Young said: "Our ongoing relationship with Oxford BioMedica has the potential to deliver significant value as we move to commercialise these discoveries".
"Oxford BioMedica has been an excellent partner and has made an important contribution to developing these library candidates.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
